The above studies encourage further assessment of pro-cognitive, and putative anxiolytic and antidepressant-like properties of TAAR1 agonists, not only in the context of negative symptoms of schizophrenia, but also other psychiatric disorders. This evidence concerns the gene TAAR1 and schizophrenia.